Skip to main content
. 2013 Apr 16;8(4):e61395. doi: 10.1371/journal.pone.0061395

Figure 5. Comparison of efficacy against infection for RTS,S/AS01 and RTS,S/AS02.

Figure 5

Comparison of efficacy against infection as a function of anti-CSP antibody titre in the absence of CSP-specific CD4+ T cells for RTS,S/AS01 (black) and RTS,S/AS02 (pink) based on the sporozoite infection model. The grey and pink shaded regions denote 95% confidence intervals for the estimated efficacy of RTS,S/AS01 and RTS,S/AS02, respectively. The substantial overlap between the two curves indicates that, conditional upon the magnitude of the induced antibody response, RTS,S/AS01 and RTS,S/AS02 have comparable efficacy. That is, the superior efficacy of RTS,S/AS01 over RTS,S/AS02 is estimated here to be due to the greater magnitude of the induced immune response and not some other property of the adjuvant.